HCA Healthcare, Inc. $HCA Shares Sold by Cooke & Bieler LP

Cooke & Bieler LP decreased its position in HCA Healthcare, Inc. (NYSE:HCA) by 29.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 86,765 shares of the company’s stock after selling 35,907 shares during the period. Cooke & Bieler LP’s holdings in HCA Healthcare were worth $40,507,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Capital World Investors lifted its stake in HCA Healthcare by 3.8% during the 3rd quarter. Capital World Investors now owns 4,959,336 shares of the company’s stock valued at $2,113,662,000 after acquiring an additional 179,443 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in HCA Healthcare by 1.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,065,225 shares of the company’s stock valued at $880,199,000 after purchasing an additional 36,414 shares during the period. Viking Global Investors LP lifted its holdings in shares of HCA Healthcare by 58.5% in the 2nd quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after buying an additional 690,773 shares during the period. Legal & General Group Plc raised its position in HCA Healthcare by 0.8% during the third quarter. Legal & General Group Plc now owns 1,124,511 shares of the company’s stock valued at $479,267,000 after acquiring an additional 8,478 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of HCA Healthcare by 1.1% during the 3rd quarter. Invesco Ltd. now owns 1,100,929 shares of the company’s stock worth $469,216,000 after purchasing an additional 11,829 shares during the period. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Trading Up 0.1%

HCA stock opened at $394.40 on Tuesday. The company has a market cap of $87.49 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 1.25 and a beta of 1.18. The firm has a 50-day moving average of $462.41 and a two-hundred day moving average of $483.23. HCA Healthcare, Inc. has a 12 month low of $330.00 and a 12 month high of $556.52.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Friday, April 24th. The company reported $7.15 EPS for the quarter, missing the consensus estimate of $7.19 by ($0.04). HCA Healthcare had a net margin of 8.89% and a negative return on equity of 295.93%. The company had revenue of $19.11 billion during the quarter, compared to analyst estimates of $19.09 billion. During the same period in the prior year, the business posted $6.45 EPS. HCA Healthcare’s revenue for the quarter was up 4.3% compared to the same quarter last year. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, equities analysts forecast that HCA Healthcare, Inc. will post 30.07 earnings per share for the current year.

HCA Healthcare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 16th will be issued a $0.78 dividend. This represents a $3.12 annualized dividend and a yield of 0.8%. The ex-dividend date is Tuesday, June 16th. HCA Healthcare’s payout ratio is presently 10.73%.

Analyst Ratings Changes

Several analysts recently commented on HCA shares. TD Cowen dropped their price target on shares of HCA Healthcare from $561.00 to $500.00 and set a “buy” rating on the stock in a research report on Monday, April 27th. Barclays dropped their target price on HCA Healthcare from $551.00 to $496.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. KeyCorp dropped their price objective on HCA Healthcare from $550.00 to $510.00 and set an “overweight” rating on the stock in a report on Monday, April 27th. Royal Bank Of Canada decreased their target price on HCA Healthcare from $593.00 to $534.00 and set an “outperform” rating on the stock in a research report on Monday, April 27th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of HCA Healthcare from $535.00 to $490.00 and set a “neutral” rating for the company in a research report on Tuesday, May 19th. Sixteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $515.77.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.